RNAZ Stock Analysis: Buy, Sell, or Hold?
RNAZ - TransCode Therapeutics, Inc. Common Stock
$4.70
-0.65 (-12.15%)
▼
5d:
-17.4%
30d:
-23.92%
90d:
-50.79%
WAIT
LOW Confidence
Analysis Updated: Jun 18, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Get Alerted When RNAZ Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: RNAZ is down 17.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: RNAZ is down 17.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: RNAZ is currently trading at $4.70, which is considered oversold relative to its 30-day fair value range of $5.10 to $6.37.
Technical Outlook: Technically, RNAZ is in a strong downtrend. Immediate support is located at $3.82, while resistance sits at $6.30. Short-term momentum is weak, with the stock down 12.1% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $10.00 (+112.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RNAZ is in a strong downtrend. Immediate support is located at $3.82, while resistance sits at $6.30. Short-term momentum is weak, with the stock down 12.1% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $10.00 (+112.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$5.10 -
$6.37
Company Quality Score
53/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
72.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BEARISH: Downward momentum (-12.1%)
- BULLISH: Trading 112.8% below Wall St target ($10.00)
- WARNING: Recommendation downgraded due to -17.4% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$5.10 -
$6.37
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.82
Resistance Level
$6.30
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-14.69
Wall Street Target
$10.00
(+112.8%)
Share & Embed Analysis
Last updated: June 19, 2026 10:25 AM ET
Data refreshes hourly during market hours. Next update: 11:25 AM
Data refreshes hourly during market hours. Next update: 11:25 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RNAZ showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 67 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$275 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 61 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 54 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 54 HOLD |
